Abstract Details
|
Richard S. Bedlack, MD, PhD, FAAN
PRESENTER |
Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Guidepoint Global. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for New Biotic. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Woolsey Pharma. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amylyx. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ITF Pharma. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Mitsubishi Tanabe America. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orphazyme. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AB Scicence. Dr. Bedlack has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for ALS Association. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Adept Field Solutions. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Apellis. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Black Swan. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clarivate. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clearview. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clean. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CM Group. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Corcept. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Health Advances. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MT Pharma America. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MJH Healthcare. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Maple Health Care. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for National Association of Managed Care Physicians. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Projects in Knowledge. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Shinkei Pharma. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Webb MD/Medscape. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Brainstorm Cell. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mallinkrodt. Dr. Bedlack has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion . Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurosense. Dr. Bedlack has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amylyx. Dr. Bedlack has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for GenieUS. The institution of Dr. Bedlack has received research support from Cytokinetics. The institution of Dr. Bedlack has received research support from Orion. The institution of Dr. Bedlack has received research support from Ultragenyx. The institution of Dr. Bedlack has received research support from MediciNova. The institution of Dr. Bedlack has received research support from Healey Center. Dr. Bedlack has received publishing royalties from a publication relating to health care. |
| No disclosure on file | |
| Paul Wicks, PhD | No disclosure on file |
| H. E. Hinson, MD, MCR, FAAN (UCSF/Zuckerberg San Francisco General Hospital) | Dr. Hinson has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. Dr. Hinson has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. |
| No disclosure on file | |
| No disclosure on file | |
| No disclosure on file | |
| Eric A. Macklin, PhD (Massachusetts General Hospital) | The institution of Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AI Therapeutics. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chase Therapeutics. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bial Biotech. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Stoparkinson Healthcare LLC. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Macklin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Macklin has received research support from Biohaven. The institution of Dr. Macklin has received research support from Clene Nanomedicine. The institution of Dr. Macklin has received research support from Mitsubishi Tanabe Pharmaceuticals America. The institution of Dr. Macklin has received research support from Prilenia. The institution of Dr. Macklin has received research support from UCB Ra Pharma. The institution of Dr. Macklin has received research support from Revalesio. The institution of Dr. Macklin has received research support from Seelos. The institution of Dr. Macklin has received research support from Calico. The institution of Dr. Macklin has received research support from Denali. The institution of Dr. Macklin has received research support from NeuroDex. The institution of Dr. Macklin has received research support from Alector. The institution of Dr. Macklin has received research support from ITB-Med. |
| Alexander Sherman (Massachusetts General Hospital) | The institution of Mr. Sherman has received research support from The ALS Association. The institution of Mr. Sherman has received research support from NIH. The institution of Mr. Sherman has received research support from FDA. The institution of Mr. Sherman has received research support from Biogen. The institution of Mr. Sherman has received research support from Amylyx Pharmaceuticals. The institution of Mr. Sherman has received research support from Mitsubishi-Tanabe Pharma America. Mr. Sherman has a non-compensated relationship as a Member, Board of Directors with ALD Connect that is relevant to AAN interests or activities. |